Gilead’s Rough Week, Grail Poaches a Data Star, & Kite Passes a Big CAR-T Trial

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.